HORIZON: A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Oct 3, 2026 - P1/2 | N=69 | Not yet recruiting | Sponsor: Biogen
First-in-human • New P1/2 trial • Amyotrophic Lateral Sclerosis • CNS Disorders • FUS • Plasma NfL • SOD1
|